207 related articles for article (PubMed ID: 24384836)
1. In vivo immunological antitumor effect of OK-432-stimulated dendritic cell transfer after radiofrequency ablation.
Nakagawa H; Mizukoshi E; Iida N; Terashima T; Kitahara M; Marukawa Y; Kitamura K; Nakamoto Y; Hiroishi K; Imawari M; Kaneko S
Cancer Immunol Immunother; 2014 Apr; 63(4):347-56. PubMed ID: 24384836
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation.
Homma S; Sagawa Y; Komita H; Koido S; Nagasaki E; Ryoma Y; Okamoto M
Cancer Immunol Immunother; 2007 Aug; 56(8):1265-74. PubMed ID: 17219148
[TBL] [Abstract][Full Text] [Related]
3. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
Ishii S; Hiroishi K; Eguchi J; Hiraide A; Imawari M
Gene Ther; 2006 Jan; 13(1):78-87. PubMed ID: 16107857
[TBL] [Abstract][Full Text] [Related]
5. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC Chemokine ligand 3/macrophage inflammatory protein-1alpha.
Iida N; Nakamoto Y; Baba T; Nakagawa H; Mizukoshi E; Naito M; Mukaida N; Kaneko S
Cancer Res; 2010 Aug; 70(16):6556-65. PubMed ID: 20663902
[TBL] [Abstract][Full Text] [Related]
8. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
[TBL] [Abstract][Full Text] [Related]
10. Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer.
Ito F; Ku AW; Bucsek MJ; Muhitch JB; Vardam-Kaur T; Kim M; Fisher DT; Camoriano M; Khoury T; Skitzki JJ; Gollnick SO; Evans SS
PLoS One; 2015; 10(11):e0143370. PubMed ID: 26599402
[TBL] [Abstract][Full Text] [Related]
11. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice.
Satoh Y; Esche C; Gambotto A; Shurin GV; Yurkovetsky ZR; Robbins PD; Watkins SC; Todo S; Herberman RB; Lotze MT; Shurin MR
J Exp Ther Oncol; 2002; 2(6):337-49. PubMed ID: 12440225
[TBL] [Abstract][Full Text] [Related]
12. Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity.
Alteber Z; Azulay M; Cafri G; Vadai E; Tzehoval E; Eisenbach L
Cancer Immunol Immunother; 2014 Apr; 63(4):369-80. PubMed ID: 24452202
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo.
Tanaka F; Yamaguchi H; Ohta M; Mashino K; Sonoda H; Sadanaga N; Inoue H; Mori M
Int J Cancer; 2002 Sep; 101(3):265-9. PubMed ID: 12209978
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells.
Luo X; Yu Y; Liang A; Xie Y; Liu S; Guo J; Wang W; Qi R; An H; Zhang M; Xu H; Guo Z; Cao X
Cell Mol Immunol; 2004 Jun; 1(3):199-204. PubMed ID: 16219168
[TBL] [Abstract][Full Text] [Related]
15. Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma.
Suzuki A; Masuda A; Nagata H; Kameoka S; Kikawada Y; Yamakawa M; Kasajima T
J Pathol; 2002 Jan; 196(1):37-43. PubMed ID: 11748640
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with dendritic cells and 5-fluorouracil elicits augmented NK cell-mediated antitumor activity through the tumor necrosis factor-alpha pathway.
Nagasaki E; Takahara A; Koido S; Sagawa Y; Aiba K; Tajiri H; Yagita H; Homma S
J Immunother; 2010 Jun; 33(5):467-74. PubMed ID: 20463601
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-4 and CpG oligonucleotide therapy suppresses the outgrowth of tumors by activating tumor-specific Th1-type immune responses.
Kajiwara A; Doi H; Eguchi J; Ishii S; Hiraide-Sasagawa A; Sakaki M; Omori R; Hiroishi K; Imawari M
Oncol Rep; 2012 Jun; 27(6):1765-71. PubMed ID: 22426807
[TBL] [Abstract][Full Text] [Related]
18. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4.
Ahmed SU; Okamoto M; Oshikawa T; Tano T; Sasai A; Kan S; Hiroshima T; Ohue H; Moriya Y; Ryoma Y; Saito M; Sato M
J Immunother; 2004; 27(6):432-41. PubMed ID: 15534487
[TBL] [Abstract][Full Text] [Related]
20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
